Design of new oxazaphosphorine anticancer drugs

Liang, J, Huang, M, Duan, W, Yu, X and Zhou, S 2007, 'Design of new oxazaphosphorine anticancer drugs', Current Pharmaceutical Design, vol. 13, no. 8, pp. 963-978.

Document type: Journal Article
Collection: Journal Articles

Title Design of new oxazaphosphorine anticancer drugs
Author(s) Liang, J
Huang, M
Duan, W
Yu, X
Zhou, S
Year 2007
Journal name Current Pharmaceutical Design
Volume number 13
Issue number 8
Start page 963
End page 978
Total pages 16
Publisher Bentham Science Publishers Ltd.
Abstract The oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten) represent an important group of therapeutic agents due to their substantial antitumor and immunomodulating activity. However, several intrinsic limitations have been uncounted during the clinical use of these oxazaphosphorines, including substantial pharmacokinetic variability, resistance and severe host toxicity. To circumvent these problems, new oxazaphosphorines derivatives have been designed and evaluated with an attempt to improve the selectivity and response with reduced host toxicity. These include mafosfamide (NSC 345842), glufosfamide (D19575, ß-Dglucosylisophosphoramide mustard), S-(-)-bromofosfamide (CBM-11), NSC 612567 (aldophosphamide perhydrothiazine) and NSC 613060 (aldophosphamide thiazolidine). Mafosfamide is an oxazaphosphorine analog that is a chemically stable 4-thioethane sulfonic acid salt of 4-hydroxy-CPA. Glufosfamide is IFO derivative in which the isophosphoramide mustard, the alkylating metabolite of IFO, is glycosidically linked to a ß-D-glucose molecule. Phase II studies of glufosfamide in the treatment of pancreatic cancer, non-small cell lung cancer (NCSLC), and recurrent glioblastoma multiform (GBM) have recently completed and Phase III trials are ongoing, while Phase I studies of intrathecal mafosfamide have recently completed for the treatment of meningeal malignancy secondary to leukemia, lymphoma, or solid tumors. S-(-)- bromofosfamide is a bromine-substituted IFO analog being evaluated in a few Phase I clinical trials. The synthesis and development of novel oxazaphosphorine analogs with favourable pharmacokinetic and pharmacodynamic properties still constitutes a great challenge for medicinal chemists and cancer pharmacologists.
Subject Basic Pharmacology
DOI - identifier 10.2174/138161207780414296
ISSN 1381-6128
Version Filter Type
Citation counts: Scopus Citation Count Cited 24 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 224 Abstract Views  -  Detailed Statistics
Created: Mon, 06 Dec 2010, 14:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us